Trial Condition(s):
Hepatic Impairment Study
12349
Not Available
Not Available
This study is to find out how the subject's body processes and reacts to the study drug, and to find out how long it remains in the subjects system after one dose. Subjects with varying degrees of liver function are being asked to participate in this study. Study results from subjects with normal liver function will be compared with study results from subjects with impaired liver function.
: - Healthy Subjects, Child Pugh A and Child Pugh B Liver Disease Patients.
No Exclusion Criteria Available
Locations | |
---|---|
Locations Clinical Pharmacology of Miami, Inc. Miami, United States, 33014 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Orlando Clinical Research Center Orlando, United States, 32809 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations New Orleans Center for Clinical Research Knoxville, United States, 37920 | Contact Us: E-mail: [email protected] Phone: Not Available |
Open Label, Phase 1 to evaluate the effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006)
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Non-randomized
Blinding:
Open Label
Assignment:
Single Group Assignment
Trial Arms:
3